S16 Ep11: Treatment Evolutions Affect First-Line Chemotherapy Selection in Metastatic Pancreatic Cancer: With Rachna T. Shroff, MD, MS, FASCO; and Kristen Spencer, DO

Metastatic pancreatic cancer management centers on balancing life-prolonging efficacy with the preservation of quality of life, as current treatments remain palliative. Clinicians prioritize aligning therapeutic choices with patient goals, symptom burden, and performance status while integrating supportive care early in the journey. The recent approval of NALIRIFOX expands the frontline armamentarium, offering a multi-agent option that requires careful consideration of toxicity profiles, particularly regarding neuropathy and diarrhea. Beyond standard chemotherapy, early identification of actionable biomarkers and enrollment in clinical trials are essential for improving outcomes. As the field evolves, the integration of targeted therapies, such as RAS inhibitors, promises to shift the treatment paradigm. Furthermore, fostering diversity and mentorship for women in gastrointestinal oncology remains vital for driving innovation in clinical trial design and patient care strategies.